Skip Navigation
American College of Physicians Logo
  • Subscribe
  • Submit a Manuscript
  • Sign In
    Sign in below to access your subscription for full content
    INDIVIDUAL SIGN IN
    Sign In|Set Up Account
    You will be directed to acponline.org to register and create your Annals account
    INSTITUTIONAL SIGN IN
    Open Athens|Shibboleth|Log In
    Annals of Internal Medicine
    SUBSCRIBE
    Subscribe to Annals of Internal Medicine.
    You will be directed to acponline.org to complete your purchase.
Annals of Internal Medicine Logo Menu
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives
  • Author Info
Advanced Search
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Reviews |3 January 2017

Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline Free

Paul G. Shekelle, MD, PhD; Sydne J. Newberry, PhD; John D. FitzGerald, MD, PhD; Aneesa Motala, BA; Claire E. O'Hanlon, MPP; Abdul Tariq, BS; Adeyemi Okunogbe, MD; Dan Han, MPA; Roberta Shanman, MLS

Paul G. Shekelle, MD, PhD
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Sydne J. Newberry, PhD
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

John D. FitzGerald, MD, PhD
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Aneesa Motala, BA
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Claire E. O'Hanlon, MPP
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Abdul Tariq, BS
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Adeyemi Okunogbe, MD
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Dan Han, MPA
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Roberta Shanman, MLS
From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

Article, Author, and Disclosure Information
Author, Article, and Disclosure Information
This article was published at www.annals.org on 1 November 2016.
  • From RAND Corporation, Santa Monica, and Veterans Affairs Greater Los Angeles Healthcare System and David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles, California.

    Disclaimer: The authors of this manuscript are responsible for its content. Statements in the manuscript should not be construed as endorsement by the Agency for Healthcare Research and Quality (AHRQ) or the U.S. Department of Health and Human Services. AHRQ retains a license to display, reproduce, and distribute the data and the report from which this manuscript was derived under the terms of the agency's contract with the author.

    Acknowledgment: The authors thank Patricia Smith for her administrative assistance on the project and acknowledge the guidance provided by the key informants and technical expert panel members on the evidence report.

    Financial Support: This project was funded under contract 290-2012-00006I from the AHRQ, U.S. Department of Health and Human Services.

    Disclosures: All authors report a grant from AHRQ during the conduct of the study. Dr. Shekelle reports personal fees from ECRI Institute outside the submitted work and royalties from UpToDate. Authors not named here have disclosed no other conflicts of interest. Disclosures can also be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M16-0461.

    Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer and Johnson & Johnson.

    Reproducible Research Statement:Study protocol: Available at http://effectivehealthcare.ahrq.gov/ehc/products/564/1992/Gout-managment-protocol-141103.pdf. Statistical code: Not applicable. Data set: Available in the full report at https://effectivehealthcare.ahrq.gov/search-for-guides-reviews-and-reports/?pageaction=displayproduct&productID=2195.

    Requests for Single Reprints: Paul G. Shekelle, MD, PhD, RAND Corporation, 1776 Main Street, Santa Monica, CA 90401; e-mail, shekelle@rand.org.

    Current Author Addresses: Drs. Shekelle and Newberry, Ms. Motala, Ms. O'Hanlon, Mr. Tariq, Ms. Han, and Ms. Shanman: RAND Corporation, 1776 Main Street, Santa Monica, CA 90401.

    Dr. FitzGerald: David Geffen School of Medicine at the University of California, Los Angeles, Rehabilitation Center, Room 32-59, 1000 Veteran Avenue, Los Angeles, CA 90095.

    Dr. Okunogbe: RAND Corporation, 1200 South Hayes Street, Arlington, VA 22202.

    Author Contributions: Conception and design: P.G. Shekelle.

    Analysis and interpretation of the data: P.G. Shekelle, S.J. Newberry, J.D. FitzGerald, C.E. O'Hanlon, A. Tariq, A. Okunogbe, D. Han.

    Drafting of the article: P.G. Shekelle, S.J. Newberry, J.D. FitzGerald, A. Motala, A. Tariq, A. Okunogbe.

    Critical revision of the article for important intellectual content: P.G. Shekelle, S.J. Newberry, J.D. FitzGerald, C.E. O'Hanlon, A. Okunogbe.

    Final approval of the article: P.G. Shekelle, S.J. Newberry, J.D. FitzGerald, A. Motala, C.E. O'Hanlon, A. Tariq, A. Okunogbe, D. Han, R. Shanman.

    Obtaining of funding: P.G. Shekelle.

    Administrative, technical, or logistic support: A. Motala.

    Collection and assembly of data: P.G. Shekelle, A. Motala, C.E. O'Hanlon, A. Tariq, A. Okunogbe, D. Han, R. Shanman.

×
  • ‹ PREV ARTICLE
  • This Issue
  • NEXT ARTICLE ›
Jump To
  • Full Article
  • FULL ARTICLE
    • Abstract
    • Methods
    • Results
    • Discussion
      1. References
  • Figures
  • Tables
  • Supplements
  • Audio/Video
  • Summary for Patients
  • Clinical Slide Sets
  • CME / MOC
  • Comments
  • Twitter Link
  • Facebook Link
  • Email Link
More
  • LinkedIn Link
  • CiteULike Link

Abstract

Background:

Gout is a common type of inflammatory arthritis in patients seen by primary care physicians.

Purpose:

To review evidence about treatment of acute gout attacks, management of hyperuricemia to prevent attacks, and discontinuation of medications for chronic gout in adults.

Data Sources:

Multiple electronic databases from January 2010 to March 2016, reference mining, and pharmaceutical manufacturers.

Study Selection:

Studies of drugs approved by the U.S. Food and Drug Administration and commonly prescribed by primary care physicians, randomized trials for effectiveness, and trials and observational studies for adverse events.

Data Extraction:

Data extraction was performed by one reviewer and checked by a second reviewer. Study quality was assessed by 2 independent reviewers. Strength-of-evidence assessment was done by group discussion.

Data Synthesis:

High-strength evidence from 28 trials (only 3 of which were placebo-controlled) shows that colchicine, nonsteroidal anti-inflammatory drugs (NSAIDs), and corticosteroids reduce pain in patients with acute gout. Moderate-strength evidence suggests that low-dose colchicine is as effective as high-dose colchicine and causes fewer gastrointestinal adverse events. Moderate-strength evidence suggests that urate-lowering therapy (allopurinol or febuxostat) reduces long-term risk for acute gout attacks after 1 year or more. High-strength evidence shows that prophylaxis with daily colchicine or NSAIDs reduces the risk for acute gout attacks by at least half in patients starting urate-lowering therapy, and moderate-strength evidence indicates that duration of prophylaxis should be longer than 8 weeks. Although lower urate levels reduce risk for recurrent acute attacks, treatment to a specific target level has not been tested.

Limitation:

Few studies of acute gout treatments, no placebo-controlled trials of management of hyperuricemia lasting longer than 6 months, and few studies in primary care populations.

Conclusion:

Colchicine, NSAIDs, and corticosteroids relieve pain in adults with acute gout. Urate-lowering therapy decreases serum urate levels and reduces risk for acute gout attacks.

Primary Funding Source:

Agency for Healthcare Research and Quality. (Protocol registration: http://effectivehealth-care.ahrq.gov/ehc/products/564/1992/Gout-managment-protocol-141103.pdf)

Gout, a common form of inflammatory arthritis, is characterized by acute intermittent episodes of synovitis that cause joint swelling and pain. Approximately 8 million persons in the United States have gout (1). It occurs when excess urate in the body crystalizes (as monosodium urate) in joint fluid, cartilage, bones, tendons, bursas, or other sites. The crystals can directly initiate an acute inflammatory attack. In some patients, acute gout attacks become progressively more frequent, protracted, and severe and may progress to a chronic inflammatory condition. In addition, some patients develop tophi, which are deposits of urate crystals at the surface of joints or in skin or cartilage.
This systematic review was proposed by the American College of Physicians (ACP) to support the development of a clinical practice guideline that would aid primary care practitioners in the management of adult patients with gout.

Methods

We developed a protocol (http://effectivehealthcare.ahrq.gov/ehc/products/564/1992/Gout-managment-protocol-141103.pdf); followed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines for reporting systematic reviews (2); and detailed search and selection processes, inclusion criteria, and evidence tables in an evidence report (3).

Key Questions

Key questions proposed by ACP were revised on the basis of input from a group of key informants, a technical expert panel, and the public. Treatment questions addressed benefits and harms of pharmacologic and dietary therapies for adults with acute gout attacks and the intermediate and long-term benefits and harms of therapies for adults with gout and hyperuricemia. Additional management questions addressed monitoring of serum urate levels and whether criteria exist to identify patients who are candidates for discontinuation of urate-lowering therapy or anti-inflammatory prophylaxis.

Data Sources and Searches

We searched (without language restrictions) for systematic reviews and original research studies in PubMed, EMBASE, the Cochrane Collaboration, and the Web of Science, using the terms “gout” and “gouty” and terms for tophi. The start date of the searches was 1 January 2010, which was at least 1 year before the search dates for the most recent systematic reviews, and the end date was 1 March 2016. Relevant references were obtained from 29 recent systematic reviews. We searched ClinicalTrials.gov from inception to 1 March 2016 and the Web of Science from 1 January 2010 through 1 March 2016, and we contacted manufacturers of prescription medications used to treat gout for recently completed studies and unpublished or non–peer-reviewed study findings in July 2014. Appendix Table 1 provides detailed search methods.

Appendix Table 1. Detailed Search Methods

Image: M160461tt4_Appendix_Table_1_Detailed_Search_Methods
Appendix Table 1. Detailed Search Methods

Study Selection

Two reviewers independently screened records (titles, abstracts, and articles) to identify reviews and studies that reported on the benefits (randomized trials) or harms (observational studies and trials) of treatment and management strategies for gout. We examined only medications approved by the U.S. Food and Drug Administration (FDA), except for nonsteroidal anti-inflammatory drugs (NSAIDs), which are commonly used to treat gout. As suggested by the ACP Clinical Guidelines Committee, we excluded pegloticase and lesinurad, which primary care physicians are unlikely to prescribe. Studies that enrolled participants with no formal gout diagnosis (based on either synovial fluid analysis or a clinical diagnosis) were excluded.

Data Extraction and Quality Assessment

Study-level details were abstracted by one reviewer and checked by a second reviewer, with reconciliation of disagreements by group discussion. Risk of bias of individual studies was assessed independently by 2 reviewers using an adapted Cochrane risk-of-bias tool (4), with reconciliation of disagreements by the project lead. A modified AMSTAR (A Measurement Tool to Assess Systematic Reviews) tool was used to assess the quality of systematic reviews (5).

Data Synthesis and Grading

We deemed studies to be too few in number and too heterogeneous to support new meta-analysis. We assessed the overall strength of evidence as high, moderate, low, or insufficient for each conclusion by using guidance suggested by the Effective Health Care Program (6). We also applied criteria proposed by Bradford Hill for causality when judging strength of evidence (7), including the strength, consistency, and specificity of the association; the temporal relationship; the “biologic gradient” or dose–response curve; the biologic plausibility; and coherence.

Role of the Funding Source

This topic was proposed by the ACP to the Agency for Healthcare Research and Quality (AHRQ) and funded by AHRQ. Staff at AHRQ and ACP helped to develop and refine the scope of the study and reviewed the draft report.

Results

The Figure shows the search and selection process that identified 155 articles meeting the inclusion criteria. Of these, 22 evaluated dietary therapy or traditional Chinese medicine; details about the inconclusive evidence from those studies are in the evidence report (3).
Figure.

Literature flow diagram.

* The number of included studies for this article differs from the number of included studies in the evidence report (3) because this review did not address all of the key questions addressed in the report.

† Results for this question are not included in this article. See the evidence report (3).

Image: M160461ff1_Figure_Literature_flow_diagram

Pharmacologic Treatment for Acute Gout

We identified evidence for several pharmacologic treatments for acute gout: colchicine, NSAIDs, corticosteroids, and animal-derived corticotropin formulation (8–35). None of the studies assessed differences in effectiveness by patient characteristics, such as age, sex, duration of the episode, history, genetic profile, baseline serum urate level, or presence of comorbidities.

Colchicine

Although colchicine was used to treat gout in the ninth century or earlier (36), its use has been evaluated in only 2 randomized, placebo-controlled trials (12, 14). These trials enrolled 184 and 43 patients, respectively, who had crystal-proven gout or met the American College of Rheumatology criteria and had mean duration of symptoms of 38 hours or less. Both studies found that patients treated with colchicine had better pain relief than placebo recipients (38% vs. 16% achieved a 50% decrease in target joint pain at 24 hours, and 41% vs. 9% achieved a 50% decrease in baseline pain score at 24 hours). The earlier trial, published in 1987, used an initial colchicine dose of 1 mg followed by 0.5 mg every 2 hours until symptom relief or adverse effects occurred (14). All of the colchicine-treated patients had gastrointestinal adverse effects by 24 hours, and 91% reported adverse effects before achieving a 50% reduction in pain intensity. The later trial compared “low-dose” (an initial dose of 1.2 mg followed by 0.6 mg 1 hour later) versus “high-dose” (an initial dose of 1.2 mg followed by 0.6 mg per hour for 6 hours) colchicine (12). Low-dose colchicine was as effective as high-dose colchicine compared with placebo and was much better tolerated; for example, 23% versus 77% of patients receiving low- and high-dose therapy reported diarrhea, and 0% versus 19% of these patients reported severe diarrhea (Table 1).

Table 1. Key Trials of Treatments for Acute Gout

Image: M160461tt1_Table_1_Key_Trials_of_Treatments_for_Acute_Gout
Table 1. Key Trials of Treatments for Acute Gout

NSAIDs

One low-quality, placebo-controlled trial assessed NSAIDs in patients with acute gout (30). This small study assessed the effect of tenoxicam (40 mg once daily) in 30 patients and found that a greater proportion of those receiving tenoxicam than those receiving placebo reported at least 50% improvement at 24 hours.
Sixteen randomized trials compared one NSAID with another (8, 9, 11, 15–19, 21–23, 27–29, 31, 32). Most studies found no statistically significant differences in outcomes between treatments, although only 3 studies enrolled more than 100 patients (9, 22, 23), meaning that most studies were small and had limited power to detect differences (Appendix Table 2).

Appendix Table 2. Randomized, Controlled Trials of NSAID Versus NSAID for Treatment of Acute Gout

Image: M160461tt5_Appendix_Table_2_Randomized_Controlled_Trials_of_NSAID_Versus_NSAID_for_Treatment_of
Appendix Table 2. Randomized, Controlled Trials of NSAID Versus NSAID for Treatment of Acute Gout

Corticosteroids

No published placebo-controlled trials assessed oral corticosteroids for acute gout. Six randomized trials compared corticosteroids (3 oral, 2 intramuscular, and 1 intravenous) versus NSAIDs. These studies, which enrolled 27 (20), 60 (13), 90 (24), 92 (33), 120 (10), and 416 (34) patients, found few differences in effectiveness or adverse events between treatments. In one study of oral corticosteroids, 90 patients presenting to the emergency department with acute arthritis suggestive of gout were randomly assigned to receive either prednisolone, 30 mg/d for 5 days, or indomethacin, 50 mg 3 times daily for 2 days and 25 mg/d for the next 3 days; all patients also received paracetamol. No statistically or clinically significant between-group differences were seen at any evaluation point (up to 14 days). More patients in the indomethacin group than the prednisolone group reported adverse events (63% vs. 27%) (24). In another study of oral corticosteroids, 120 patients who presented to family physicians with acute monoarthritis and had monosodium urate crystals on synovial fluid examination were randomly assigned to prednisolone, 35 mg/d, or naproxen, 500 mg twice daily. Over the subsequent 4 days, no statistically significant differences in effectiveness outcomes were observed between groups. Equal proportions of patients in both groups reported an adverse event (66% vs. 63%) (10). The third study of oral corticosteroids randomly assigned 416 patients with a clinical diagnosis of gout with symptoms lasting less than 3 days to indomethacin or prednisolone for 5 days. There were no important statistically or clinically significant differences in pain outcomes or overall adverse events. Gastrointestinal adverse events were more common in the indomethacin-treated patients, and skin rash was more common in the prednisolone-treated patients (34) (Table 1).

Corticotropin

No published placebo-controlled trials tested corticotropin for acute gout. Two randomized, controlled trials compared intramuscular corticotropin versus other active agents. One evaluated corticotropin, 40 IU, versus triamcinolone, 60 mg, both given intramuscularly only once (26); the other evaluated corticotropin, 40 IU once, versus indomethacin, 50 mg 4 times a day until pain abated (25). In the former study, patients treated with triamcinolone required fewer reinjections for inadequate pain relief than those treated with corticotropin at up to 30 days of follow-up (5 vs. 9 patients; P = 0.11). In the latter study, pain relief was faster with corticotropin than with oral indomethacin (3 vs. 24 hours to total pain relief), and at the dose of 50 mg 4 times a day, 55% of indomethacin-treated patients reported gastrointestinal adverse events (no adverse events were reported by patients receiving corticotropin) (Table 1).

Summary

Despite the small number of placebo-controlled trials, we judged the strength of evidence as high that colchicine, NSAIDs, and corticosteroids relieve pain in patients with acute gout, based on the known physiology of gout, the known mechanism of action of these drugs, the proven effectiveness of these medications in other painful or inflammatory conditions, and evidence of equivalence in head-to-head trials of patients with acute gout. We judged the evidence for use of corticotropin to be of moderate strength because of high risk of bias in the only 2 head-to-head randomized trials.

Pharmacologic Management of Hyperuricemia in Patients With Gout

We found 11 systematic reviews (37–47), 1 meta-analysis (48), 1 new abstract (49), 5 secondary analyses (50–54) of trials already included in the systematic reviews, 9 new trials assessing effectiveness (55–63), and 26 studies of adverse effects that addressed this question (64–89). Four large randomized trials of febuxostat provided most of the effectiveness evidence: APEX (Allopurinol- and Placebo-Controlled Efficacy Study of Febuxostat) (90), FACT (Febuxostat versus Allopurinol Controlled Trial) (91), the CONFIRMS (Confirmation of Febuxostat in Reducing and Maintaining Serum Urate) trial (92), and the open-label EXCEL (Febuxostat/Allopurinol Comparative Extension Long-Term) study (93). The details of these studies are presented in Table 2. More than 90% of enrolled participants were men; mean age was approximately 52 years, and mean baseline serum urate level was approximately 583 µmol/L (9.8 mg/dL).

Table 2. Key Trials of Urate-Lowering Therapy in Patients With Gout

Image: M160461tt2_Table_2_Key_Trials_of_Urate-Lowering_Therapy_in_Patients_With_Gout
Table 2. Key Trials of Urate-Lowering Therapy in Patients With Gout
Across the studies, patients were randomly assigned to various doses of febuxostat (40, 80, 120, and/or 240 mg/d; doses >80 mg/d are not FDA-approved), allopurinol, or placebo, with adjustment for renal insufficiency. Patients in all studies received prophylaxis with colchicine or naproxen when starting urate-lowering therapy. The findings were as follows. First, all active therapies decreased serum urate levels compared with placebo. Second, no important differences were seen between treatment groups or between active treatment and placebo in the frequency of acute gout attacks. Third, in the long-term extension study (EXCEL), patients achieving a serum urate level less than 357 µmol/L (<6 mg/dL) had progressive decreases in their risk for acute gout attacks (to about 5% at 12 months and near zero at 32 months), regardless of choice of urate-lowering therapy. Fourth, febuxostat, 80 mg/d, was more effective than allopurinol, 300 mg/d, at decreasing serum urate levels. Fifth, no major or important differences were seen in outcomes or total adverse events between allopurinol, 300 mg/d, and febuxostat, 40 mg/d. Sixth, discontinuation of colchicine or naproxen prophylaxis after 8 weeks in both APEX and FACT was associated with a spike in acute gout attacks not seen in CONFIRMS, which maintained prophylaxis throughout the 6-month duration of the study. Finally, studies assessing comparative effectiveness in subgroups were sparse but generally found no differences in clinical outcomes, although they had limited power to detect such differences (3). Several smaller studies had findings similar to those of the larger randomized, controlled trials (49, 55, 63, 94, 95).
Appendix Table 3 presents selected adverse events seen in the randomized, controlled trials of urate-lowering therapy. Differences between active treatments and between active treatments and placebo were mostly small and not statistically significant. Although skin rash was not statistically significantly more likely in allopurinol-treated patients in these trials, observational evidence suggested that allopurinol is a cause of DRESS (drug rash with eosinophilia and systemic symptoms) syndrome (65, 68–70, 72) and is more common in patients with the HLA-B*5801 allele (41, 62, 66, 74, 79, 86, 88).

Appendix Table 3. Adverse Events of Urate-Lowering Therapy From Selected Randomized, Controlled Trials*

Image: M160461tt6_Appendix_Table_3_Adverse_Events_of_Urate-Lowering_Therapy_From_Selected_Randomized_Co
Appendix Table 3. Adverse Events of Urate-Lowering Therapy From Selected Randomized, Controlled Trials*
In summary, high-strength evidence suggests that urate-lowering therapy reduces serum urate levels. However, it does not reduce the risk for acute gout attacks in the first 6 months. Long-term extension studies show that patients continuing urate-lowering therapy who achieve serum urate reductions have fewer acute gout attacks, which supports the moderate-strength conclusion that urate-lowering therapy reduces the risk for such attacks after about 1 year.

Prophylaxis Against Acute Gout Attacks at Initiation of Urate-Lowering Therapy

Initiation of therapy to decrease serum urate levels is associated with an increased frequency of acute gout attacks (96). This is a likely explanation for the observation that use of urate-lowering therapy does not reduce the frequency of acute gout attacks compared with placebo for the first 6 months. More than 30 years ago, investigators tested colchicine as prophylaxis against acute attacks for patients starting uricosuric therapy (97, 98). However, the first randomized, placebo-controlled trial of colchicine prophylaxis at initiation of allopurinol therapy was not published until 2004 (57). In this study, investigators randomly assigned 51 patients to colchicine, 0.6 mg twice daily, or placebo when starting allopurinol therapy at 100 mg once daily and titrating upward, with a target serum urate level of 387 µmol/L (6.5 mg/dL). Occurrence of gout attacks was recorded by patient recall at 3- and 6-month visits. Among 43 patients who completed the trial (mean age, 63 years; >50% male; >60% with tophi; approximately 10% with chronic renal insufficiency), 77% of placebo recipients versus 33% of colchicine-treated patients had gout attacks (P = 0.008). During the first 3 months of treatment, placebo recipients averaged about 2 attacks and colchicine-treated patients averaged about 0.5 attack. From months 3 to 6, this advantage diminished, with about 1 attack per patient in the placebo group and almost no attacks in the colchicine group. Diarrhea was much more common in colchicine-treated patients (43%) than in placebo recipients (approximately 4%).
The use of prophylactic therapy concomitant with the initiation of urate-lowering therapy has been the recommended standard of care for many years (99, 100). All 3 of the recent large trials of urate-lowering therapy (FACT, APEX, and CONFIRMS) used prophylaxis with colchicine or NSAIDs (90–92), even though no randomized trials had assessed NSAIDs as a prophylactic therapy for urate-lowering therapy. In both FACT and APEX, the number of acute attacks spiked after discontinuation of prophylaxis at 8 weeks, with an approximate doubling of the proportion of patients reporting an attack (from 20% before to 40% after discontinuation). CONFIRMS, which continued prophylaxis for the entire 6 months of the trial, saw no spike in attacks.
One randomized trial with high risk of bias compared different durations of colchicine prophylaxis in patients with gout initiating allopurinol therapy (59). However, the outcome measure was “any evidence of recurrence of gouty arthritis,” and the criteria for this clinical event and loss to follow-up were not specified.
Wortmann and colleagues collected adverse event data from all 3 of the major trials of febuxostat and allopurinol and pooled data from FACT and APEX (56). None of these trials randomly assigned patients to different prophylaxis regimens; rather, selection bias was potentially present because assignment was at the discretion of the treating physician. In all 3 studies, upper respiratory infection was the most frequently reported adverse event (8% to 9% in each group, with no statistically significant difference). Overall, adverse events were higher with colchicine prophylaxis than with naproxen prophylaxis (55% vs. 44%). Diarrhea was about 3 times more common with colchicine than with naproxen (8.4% vs. 2.7%). In CONFIRMS, no statistically significant difference was seen in overall adverse events reported (about 55% in both groups), but gastrointestinal and abdominal pains were about 3 times more frequent in naproxen-treated patients (3.2% vs. 1.2%). Headache was more commonly reported in colchicine-treated patients (2.8% vs. 0.9%).
In summary, high-strength evidence suggests that prophylaxis with either colchicine or NSAIDs reduces the risk for acute gout attacks in patients initiating urate-lowering therapy. The optimal duration of such prophylactic therapy is unknown, but moderate-strength evidence suggests that it should be longer than 8 weeks.

Treatment Monitoring of Patients With Gout

A large body of evidence (which includes the fact that urate is soluble up to a concentration of about 404 µmol/L [6.8 mg/dL], above which precipitation may begin [101]) supports the hypothesis that lower serum urate levels are causally associated with a lower rate of acute gout attacks. A post hoc analysis that combined data from 3 large trials (ULT, FACT, and APEX) provided the best clinical data about the relationship between achieved urate levels and risk for acute gout attacks (102). That analysis included more than 1800 patients with gout and a baseline serum urate level of 476 µmol/L (8.0 mg/dL) or greater. The achieved urate level was 1 of 3 variables (along with baseline presence of tophi and percentage change in serum urate level from baseline) that were associated with acute gout attacks requiring treatment (adjusted odds ratio, 1.42 [95% CI, 1.16 to 1.73] and 2.70 [CI, 1.72 to 4.22] at 6 and 12 months after initiation of therapy, respectively). Patients who achieved a serum urate level less than 357 µmol/L (<6.0 mg/dL) at the end of 1 year had a risk for acute gout attacks of approximately 5%, whereas patients with levels at or above 357 µmol/L (≥6.0 mg/dL) had risks of about 10% to 15%. Other reports, including analyses from several retrospective cohort studies, support a relationship between achieved lower serum urate levels and reduced risk for acute gout attacks (103–108). One study that reported outcomes for a cohort of 158 patients with incident gout who were followed for a mean of 13 years found that 70% had a flare during the extended follow-up and that higher urate levels were predictive of a subsequent acute flare (odds ratio, 1.35 [CI, 1.2 to 1.5]) (109).
There are potential nonarticular impacts of hyperuricemia in patients with gout that may be affected by serum urate levels. One retrospective observational study of U.S. veterans with gout used the U.S. Department of Veterans Affairs data warehouse to follow 2116 patients for a mean of 6.5 years. Comparing patients with high versus low serum urate levels, the investigators reported about a 2-fold difference in new diagnoses of kidney disease (4% vs. 2% at year 1 and 9% vs. 5% at year 3, respectively) (110). A second study used U.S. claims data to identify 24 108 pairs of patients with gout who were or were not treated with urate-lowering therapy and were followed for slightly more than a year. Cardiovascular events were common in both groups (incidence rates were 24% and 21%), but there were no statistically significant differences in the composite outcome or its components between groups (111).
In summary, the only way to assess whether urate-lowering therapy in patients with gout is having the desired effect on serum urate levels is by monitoring, but no direct evidence supports or refutes the value of such monitoring. The notion that decreasing serum urate levels will reduce the risk for acute gout attacks is supported by physiology and observational evidence. The evidence base for use of serum urate level as a target value for treatment is limited by the lack of any trial that has based treatment decisions on different specific targets (such as a target of 416 vs. 357 µmol/L [7.0 vs. 6.0 mg/dL]) or any target as opposed to treating symptoms. Treating to a target necessarily means increasing doses of medication in patients who may be asymptomatic. The value of such a strategy has yet to be proved, and examples exist from other studies using intermediary biomarkers (such as elevated blood pressure or blood glucose level or low hemoglobin level), in which treating to a target resulted in more adverse effects than benefits. Thus, despite the strong biologic appeal of such a strategy and its advocacy by major specialty society guidelines (99, 100, 112), we judged the strength of evidence for monitoring to be low.

Discontinuation of Pharmaceutical Management for Patients Receiving Medications for Chronic Gout

Three prospective observational cohort studies found that some patients who were currently being treated remained asymptomatic for up to 2 or 3 years after urate-lowering therapy was stopped and that serum urate levels in the presence or absence of treatment were strong predictors of which patients remained asymptomatic (113–115). Because a strategy of treatment discontinuation has never been tested in a clinical trial, we judged the strength of evidence to be insufficient that criteria exist to identify patients for whom urate-lowering therapy can be safely discontinued.

Discussion

A principal finding of this review is that high-strength evidence suggests that colchicine, NSAIDs, and corticosteroids help reduce symptoms in patients with acute gout (Table 3). Despite the limited number of placebo-controlled trials, we were able to reach strong conclusions due to specific features of gout, namely that symptoms result from an inflammatory reaction to the deposition of urate crystals, which occurs when the level of urate increases above its saturation point in the blood. Hence, in an era that predated the widespread practice of placebo-controlled trial testing of therapies, clinicians prescribed anti-inflammatory medications to treat symptoms of acute gout.

Table 3. Summary of Prior Knowledge, Findings From the Systematic Review, and Strength of Evidence, by Key Question

Image: M160461tt3_Table_3_Summary_of_Prior_Knowledge_Findings_From_the_Systematic_Review_and_Strength_o
Table 3. Summary of Prior Knowledge, Findings From the Systematic Review, and Strength of Evidence, by Key Question
Corticosteroids are among the most powerful and effective anti-inflammatory medications available. Although no randomized, placebo-controlled trials have tested their use in acute gout, corticosteroids have proven efficacy in other inflammatory conditions, which increases our confidence that they are effective in treating the inflammatory reaction in acute gout. With regard to the management of hyperuricemia in patients with gout, we likewise used direct and indirect evidence to reach conclusions about the effectiveness of urate-lowering therapy at reducing the risk for acute gout attacks over time, despite the fact that this outcome has not been studied in any placebo-controlled trial lasting longer than a few months (Table 3). We based our rating of moderate strength of evidence on the high-strength evidence that urate-lowering therapy reduces serum urate levels, that serum urate level is a strong predictor of risk for acute gout attacks, and that the open-label extension studies of urate-lowering therapy trials have shown a graded relationship between the serum urate level achieved and the risk for acute gout attacks. We concluded that after the initial period of increased risk for acute gout attacks associated with initiation of urate-lowering therapy, such therapy reduces the risk for acute attacks. The increased risk during the initial period can be reduced with concurrent use of anti-inflammatory prophylaxis.
Our review reached stronger strength-of-evidence ratings than some prior reviews, particularly Cochrane reviews, that concluded that the strength of evidence is “inconclusive” with regard to corticosteroids (116), “low-quality” with regard to colchicine (117), “limited” with regard to NSAIDs (118), and “low-moderate” with regard to allopurinol (44). Non-Cochrane reviews tended to reach stronger conclusions (for example, “all therapies were found to be effective” [119]).
The most important question to be answered for the treatment of gout in primary care is whether using urate-lowering therapy to treat all patients to a specific goal, such as less than 357 µmol/L (<6.0 mg/dL), improves patient outcomes. This concept of “treat-to-target” is supported by indirect evidence but has not been tested. Guidelines and recommendations about treatment target thresholds vary; for example, less than 357 µmol/L (<6.0 mg/dL) is the most commonly suggested threshold, but recent American College of Rheumatology guidelines suggest a threshold of less than 297 µmol/L (<5.0 mg/dL) for some patients “to improve signs and symptoms of gout” (100). However, for many patients whose gout is clinically well-controlled (no flares) during urate-lowering therapy, no direct data support such targets. In fact, the results of one cohort study suggest that once gout has been asymptomatic for 5 years, urate-lowering therapy might be discontinued for many years as long as serum urate levels remain acceptable (for example, <416 µmol/L [<7 mg/dL]) (114).
Our review identified several limitations beyond the lack of placebo-controlled studies. For many of the questions of interest, data were not reported on the subgroups or outcomes of interest. Only 10 studies explicitly stated that patients came exclusively from primary care sites or included such patients. We thus judged this evidence to be moderately applicable to primary care.
In summary, use of colchicine, NSAIDs, and corticosteroids to relieve symptoms of acute gout attacks is supported by high-strength evidence. In addition, high-strength evidence suggests that urate-lowering therapy with allopurinol or febuxostat decreases serum urate levels, and moderate-strength evidence shows that it reduces the risk for acute gout attacks after several months. In patients initiating urate-lowering therapy, high-strength evidence supports use of prophylactic colchicine or NSAIDs for more than 8 weeks to reduce the risk for acute gout attacks. Use of a treat-to-target strategy for patients with gout and hyperuricemia has logical appeal and is supported by observational evidence but has not been experimentally tested. A long-term trial of a treat-to-target strategy is the most important research need for the management of gout in primary care.

References

  1. Zhu
    Y
    Pandya
    BJ
    Choi
    HK
    Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007–2008.
    Arthritis Rheum
    2011
    63
    3136
    41
    PubMed
    CrossRef
    PubMed
  2. Moher
    D
    Liberati
    A
    Tetzlaff
    J
    Altman
    DG
    PRISMA Group
    Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
    Ann Intern Med
    2009
    151
    264
    9
    CrossRef
    PubMed
  3. Shekelle
    PG
    Fitzgerald
    J
    Newberry
    SJ
    Motala
    A
    O'Hanlon
    CE
    Okunogbe
    A
    et al
    Management of Gout. Comparative Effectiveness Review no. 176. (Prepared by the Southern California Evidence-based Practice Center under contract no. 290-2012-00006-I.) AHRQ publication no.16-EHC017-EF.
    Rockville
    Agency for Healthcare Research and Quality
    2016
  4. Higgins
    JP
    Altman
    DG
    Gøtzsche
    PC
    Jüni
    P
    Moher
    D
    Oxman
    AD
    et al
    Cochrane Bias Methods Group
    The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.
    BMJ
    2011
    343
    d5928
    .
    PubMed
    CrossRef
    PubMed
  5. Shea
    BJ
    Grimshaw
    JM
    Wells
    GA
    Boers
    M
    Andersson
    N
    Hamel
    C
    et al
    Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews.
    BMC Med Res Methodol
    2007
    7
    10
    .
    PubMed
    CrossRef
    PubMed
  6. Agency for Healthcare Research and Quality
    Methods Guide for Effectiveness and Comparative Effectiveness Reviews. AHRQ publication no. 10(14)-EHC063-EF.
    Rockville
    Agency for Healthcare Research and Quality
    2014
  7. Hill
    AB
    The environment and disease: association or causation?
    Proc R Soc Med
    1965
    58
    295
    300
    PubMed
    PubMed
  8. Maccagno
    A
    Di Giorgio
    E
    Romanowicz
    A
    Effectiveness of etodolac (‘Lodine') compared with naproxen in patients with acute gout.
    Curr Med Res Opin
    1991
    12
    423
    9
    PubMed
    CrossRef
    PubMed
  9. Schumacher
    HR
    Berger
    MF
    Li-Yu
    J
    Perez-Ruiz
    F
    Burgos-Vargas
    R
    Li
    C
    Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial.
    J Rheumatol
    2012
    39
    1859
    66
    PubMed
    CrossRef
    PubMed
  10. Janssens
    HJ
    Janssen
    M
    van de Lisdonk
    EH
    van Riel
    PL
    van Weel
    C
    Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.
    Lancet
    2008
    371
    1854
    60
    PubMed
    CrossRef
    PubMed
  11. Li
    T
    Chen
    SL
    Dai
    Q
    Han
    XH
    Li
    ZG
    Wu
    DH
    et al
    Etoricoxib versus indomethacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial.
    Chin Med J (Engl)
    2013
    126
    1867
    71
    PubMed
    PubMed
  12. Terkeltaub
    RA
    Furst
    DE
    Bennett
    K
    Kook
    KA
    Crockett
    RS
    Davis
    MW
    High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.
    Arthritis Rheum
    2010
    62
    1060
    8
    PubMed
    CrossRef
    PubMed
  13. Zhang
    YK
    Yang
    H
    Zhang
    JY
    Song
    LJ
    Fan
    YC
    Comparison of intramuscular compound betamethasone and oral diclofenac sodium in the treatment of acute attacks of gout.
    Int J Clin Pract
    2014
    68
    633
    8
    PubMed
    CrossRef
    PubMed
  14. Ahern
    MJ
    Reid
    C
    Gordon
    TP
    McCredie
    M
    Brooks
    PM
    Jones
    M
    Does colchicine work? The results of the first controlled study in acute gout.
    Aust N Z J Med
    1987
    17
    301
    4
    PubMed
    CrossRef
    PubMed
  15. Cheng
    TT
    Lai
    HM
    Chiu
    CK
    Chem
    YC
    A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis.
    Clin Ther
    2004
    26
    399
    406
    PubMed
    CrossRef
    PubMed
  16. Shrestha
    M
    Morgan
    DL
    Moreden
    JM
    Singh
    R
    Nelson
    M
    Hayes
    JE
    Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis.
    Ann Emerg Med
    1995
    26
    682
    6
    PubMed
    CrossRef
    PubMed
  17. Altman
    RD
    Honig
    S
    Levin
    JM
    Lightfoot
    RW
    Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study.
    J Rheumatol
    1988
    15
    1422
    6
    PubMed
    PubMed
  18. Eberl
    R
    Dunky
    A
    Meclofenamate sodium in the treatment of acute gout. Results of a double-blind study.
    Arzneimittelforschung
    1983
    33
    641
    3
    PubMed
    PubMed
  19. Ruotsi
    A
    Vainio
    U
    Treatment of acute gouty arthritis with proquazone and indomethacin. A comparative, double-blind trial.
    Scand J Rheumatol Suppl.
    1978
    15
    7
    PubMed
  20. Alloway
    JA
    Moriarty
    MJ
    Hoogland
    YT
    Nashel
    DJ
    Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis.
    J Rheumatol
    1993
    20
    111
    3
    PubMed
    PubMed
  21. Lederman
    R
    A double-blind comparison of etodolac and high doses of naproxen in the treatment of acute gout.
    Adv Ther
    1990
    7
    344
    54
  22. Schumacher
    HR
    Jr
    Boice
    JA
    Daikh
    DI
    Mukhopadhyay
    S
    Malmstrom
    K
    Ng
    J
    et al
    Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis.
    BMJ
    2002
    324
    1488
    92
    PubMed
    CrossRef
    PubMed
  23. Rubin
    BR
    Burton
    R
    Navarra
    S
    Antigua
    J
    Londoño
    J
    Pryhuber
    KG
    et al
    Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.
    Arthritis Rheum
    2004
    50
    598
    606
    PubMed
    CrossRef
    PubMed
  24. Man
    CY
    Cheung
    IT
    Cameron
    PA
    Rainer
    TH
    Comparison of oral prednisolone/paracetamol and oral indomethacin/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial.
    Ann Emerg Med
    2007
    49
    670
    7
    PubMed
    CrossRef
    PubMed
  25. Axelrod
    D
    Preston
    S
    Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout.
    Arthritis Rheum
    1988
    31
    803
    5
    PubMed
    CrossRef
    PubMed
  26. Siegel
    LB
    Alloway
    JA
    Nashel
    DJ
    Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of acute gouty arthritis.
    J Rheumatol
    1994
    21
    1325
    7
    PubMed
    PubMed
  27. Weiner
    GI
    White
    SR
    Weitzner
    RI
    Rubinstein
    HM
    Double-blind study of fenoprofen versus phenylbutazone in acute gouty arthritis.
    Arthritis Rheum
    1979
    22
    425
    6
    PubMed
    CrossRef
    PubMed
  28. Douglas
    G
    Thompson
    M
    A comparison of phenylbutazone and flufenamic acid in the treatment of acute gout.
    Ann Phys Med
    1970
    10
    275
    80
    PubMed
    PubMed
  29. Butler
    RC
    Goddard
    DH
    Higgens
    CS
    Hollingworth
    P
    Pease
    CT
    Stodell
    MA
    et al
    Double-blind trial of flurbiprofen and phenylbutazone in acute gouty arthritis.
    Br J Clin Pharmacol
    1985
    20
    511
    3
    PubMed
    CrossRef
    PubMed
  30. de la Torre
    G
    A comparative, double-blind, parallel study with tenoxicam vs placebo in acute in acute gouty arthritis.
    Invest Med Int
    1987
    14
    92
    7
  31. Lomen
    PL
    Turner
    LF
    Lamborn
    KR
    Winblad
    MA
    Sack
    RL
    Brinn
    EL
    Flurbiprofen in the treatment of acute gout. A comparison with indomethacin.
    Am J Med
    1986
    80
    134
    9
    PubMed
    CrossRef
    PubMed
  32. Siegmeth
    W
    Placheta
    P
    [Double-blind trial: ketoprofen versus phenylbutazone in acute gouty arthritis (author's transl)].
    Wien Klin Wochenschr
    1976
    88
    535
    7
    PubMed
    PubMed
  33. Liu
    Y
    Li
    ZC
    Chen
    JB
    Yu
    TT
    Cui
    C
    Zhang
    HB
    Therapeutic efficacy of small doses of colchicine combined with glucocorticoid for acute gouty arthritis [in Chinese].
    Medical Journal of Chinese People's Liberation Army.
    2015
    40
  34. Rainer
    TH
    Cheng
    CH
    Janssens
    HJ
    Man
    CY
    Tam
    LS
    Choi
    YF
    et al
    Oral prednisolone in the treatment of acute gout: a pragmatic, multicenter, double-blind, randomized trial.
    Ann Intern Med
    2016
    164
    464
    71
    CrossRef
    PubMed
  35. Zhang
    S
    Zhang
    Y
    Liu
    P
    Zhang
    W
    Ma
    JL
    Wang
    J
    Efficacy and safety of etoricoxib compared with NSAIDs in acute gout: a systematic review and a meta-analysis.
    Clin Rheumatol
    2016
    35
    151
    8
    PubMed
    CrossRef
    PubMed
  36. Geronikolou
    SA
    Treatment of gout in a recently published 9th century manuscript of Rhazes.
    Vesalius
    2014
    20
    95
    8
    PubMed
    PubMed
  37. Manara
    M
    Bortoluzzi
    A
    Favero
    M
    Prevete
    I
    Scirè
    CA
    Bianchi
    G
    et al
    Italian Society of Rheumatology recommendations for the management of gout.
    Reumatismo
    2013
    65
    4
    21
    PubMed
    PubMed
  38. Tayar
    JH
    Lopez-Olivo
    MA
    Suarez-Almazor
    ME
    Febuxostat for treating chronic gout.
    Cochrane Database Syst Rev
    2012
    11
    CD008653
    .
    PubMed
    PubMed
  39. Faruque
    LI
    Ehteshami-Afshar
    A
    Wiebe
    N
    Tjosvold
    L
    Homik
    J
    Tonelli
    M
    A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
    Semin Arthritis Rheum
    2013
    43
    367
    75
    PubMed
    CrossRef
    PubMed
  40. Latourte
    A
    Bardin
    T
    Richette
    P
    Prophylaxis for acute gout flares after initiation of urate-lowering therapy.
    Rheumatology (Oxford)
    2014
    53
    1920
    6
    PubMed
    CrossRef
    PubMed
  41. Ramasamy
    SN
    Korb-Wells
    CS
    Kannangara
    DR
    Smith
    MW
    Wang
    N
    Roberts
    DM
    et al
    Allopurinol hypersensitivity: a systematic review of all published cases, 1950–2012.
    Drug Saf
    2013
    36
    953
    80
    PubMed
    CrossRef
    PubMed
  42. Ye
    P
    Yang
    S
    Zhang
    W
    Lv
    Q
    Cheng
    Q
    Mei
    M
    et al
    Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: a systematic review and meta-analysis.
    Clin Ther
    2013
    35
    180
    9
    PubMed
    CrossRef
    PubMed
  43. Seth
    R
    Kydd
    AS
    Falzon
    L
    Bombardier
    C
    van der Heijde
    DM
    Edwards
    CJ
    Preventing attacks of acute gout when introducing urate-lowering therapy: a systematic literature review.
    J Rheumatol Suppl
    2014
    92
    42
    7
    PubMed
    CrossRef
    PubMed
  44. Seth
    R
    Kydd
    AS
    Buchbinder
    R
    Bombardier
    C
    Edwards
    CJ
    Allopurinol for chronic gout.
    Cochrane Database Syst Rev.
    2014
    CD006077
    .
    PubMed
  45. Kydd
    AS
    Seth
    R
    Buchbinder
    R
    Edwards
    CJ
    Bombardier
    C
    Uricosuric medications for chronic gout.
    Cochrane Database Syst Rev.
    2014
    CD010457
    .
    PubMed
  46. Castrejon
    I
    Toledano
    E
    Rosario
    MP
    Loza
    E
    Pérez-Ruiz
    F
    Carmona
    L
    Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis.
    Rheumatol Int
    2015
    35
    1127
    37
    PubMed
    CrossRef
    PubMed
  47. van Echteld
    IA
    van Durme
    C
    Falzon
    L
    Landewé
    RB
    van der Heijde
    DM
    Aletaha
    D
    Treatment of gout patients with impairment of renal function: a systematic literature review.
    J Rheumatol Suppl
    2014
    92
    48
    54
    PubMed
    CrossRef
    PubMed
  48. Chohan
    S
    Becker
    MA
    MacDonald
    PA
    Chefo
    S
    Jackson
    RL
    Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol.
    Arthritis Care Res (Hoboken)
    2012
    64
    256
    61
    PubMed
    CrossRef
    PubMed
  49. Saag
    KG
    Becker
    MA
    Whelton
    A
    MacDonald
    PA
    Zhou
    Y
    Gunawardhana
    L
    Effect of febuxostat on serum urate levels in gout subjects with hyperuricemia and moderate-to-severe renal impairment: a randomized controlled trial.
    Arthritis Rheum
    2013
    65
    S498
    9
  50. Becker
    MA
    MacDonald
    PA
    Hunt
    B
    Gunawardhana
    L
    Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
    Nucleosides Nucleotides Nucleic Acids
    2011
    30
    1011
    7
    PubMed
    CrossRef
    PubMed
  51. Becker
    MA
    MacDonald
    PA
    Hunt
    BJ
    Jackson
    RL
    Diabetes and gout: efficacy and safety of febuxostat and allopurinol.
    Diabetes Obes Metab
    2013
    15
    1049
    55
    PubMed
    CrossRef
    PubMed
  52. Goldfarb
    DS
    MacDonald
    PA
    Hunt
    B
    Gunawardhana
    L
    Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors.
    J Rheumatol
    2011
    38
    1385
    9
    PubMed
    CrossRef
    PubMed
  53. Jackson
    RL
    Hunt
    B
    MacDonald
    PA
    The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age.
    BMC Geriatr
    2012
    12
    11
    .
    PubMed
    CrossRef
    PubMed
  54. Wells
    AF
    MacDonald
    PA
    Chefo
    S
    Jackson
    RL
    African American patients with gout: efficacy and safety of febuxostat vs allopurinol.
    BMC Musculoskelet Disord
    2012
    13
    15
    .
    PubMed
    CrossRef
    PubMed
  55. Huang
    X
    Du
    H
    Gu
    J
    Zhao
    D
    Jiang
    L
    Li
    X
    et al
    An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia.
    Int J Rheum Dis
    2014
    17
    679
    86
    PubMed
    CrossRef
    PubMed
  56. Wortmann
    RL
    Macdonald
    PA
    Hunt
    B
    Jackson
    RL
    Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Clin Ther
    2010
    32
    2386
    97
    PubMed
    CrossRef
    PubMed
  57. Borstad
    GC
    Bryant
    LR
    Abel
    MP
    Scroggie
    DA
    Harris
    MD
    Alloway
    JA
    Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis.
    J Rheumatol
    2004
    31
    2429
    32
    PubMed
    PubMed
  58. Gibson
    T
    Rodgers
    V
    Potter
    C
    Simmonds
    HA
    Allopurinol treatment and its effect on renal function in gout: a controlled study.
    Ann Rheum Dis
    1982
    41
    59
    65
    PubMed
    CrossRef
    PubMed
  59. Karimzadeh
    H
    Nazari
    J
    Mottaghi
    P
    Kabiri
    P
    Different duration of colchicine for preventing recurrence of gouty arthritis.
    J Res Med Sci
    2006
    11
    104
    7
  60. Holland
    R
    McGill
    NW
    Comprehensive dietary education in treated gout patients does not further improve serum urate.
    Intern Med J
    2015
    45
    189
    94
    PubMed
    CrossRef
    PubMed
  61. Scott
    JT
    Comparison of allopurinol and probenecid.
    Ann Rheum Dis
    1966
    25
    623
    6
    PubMed
    CrossRef
    PubMed
  62. Yu
    KH
    Lai
    JH
    Hsu
    PN
    Chen
    DY
    Chen
    CJ
    Lin
    HY
    Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Scand J Rheumatol
    2016
    45
    304
    11
    PubMed
    CrossRef
    PubMed
  63. Xu
    S
    Liu
    X
    Ming
    J
    Chen
    S
    Wang
    Y
    Liu
    X
    et al
    A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia.
    Int J Rheum Dis
    2015
    18
    669
    78
    PubMed
    CrossRef
    PubMed
  64. Stamp
    LK
    Taylor
    WJ
    Jones
    PB
    Dockerty
    JL
    Drake
    J
    Frampton
    C
    et al
    Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol.
    Arthritis Rheum
    2012
    64
    2529
    36
    PubMed
    CrossRef
    PubMed
  65. Gilchrist
    MJ
    Hebert
    B
    Drug reaction with eosinophilia and systemic symptoms (DRESS).
    J Gen Intern Med
    2011
    26
    S423
    .
  66. Tassaneeyakul
    W
    Jantararoungtong
    T
    Chen
    P
    Lin
    PY
    Tiamkao
    S
    Khunarkornsiri
    U
    et al
    Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Pharmacogenet Genomics
    2009
    19
    704
    9
    PubMed
    CrossRef
    PubMed
  67. Becker
    MA
    Fitz-Patrick
    D
    Storgard
    C
    Cravets
    M
    Baumgartner
    S
    A large-scale, multicenter, prospective, open-label, 6-month study to evaluate the safety of allopurinol monotherapy in patients with gout.
    Arthritis Rheum
    2013
    65
    S502
    S3
  68. Chaudrey
    K
    Khan
    M
    Madhoun
    M
    Kastens
    D
    Allopurinol-induced DRESS syndrome: a reversible fatality.
    Am J Gastroenterol
    2013
    108
    S153
    .
  69. Ibie
    NC
    Alper
    AB
    She is all dressed up: a case of allopurinol deadly complication.
    J Investig Med
    2014
    62
    504
    5
  70. Weiss
    KM
    Jain
    R
    Wells
    C
    Agrawal
    VA
    A case of allopurinol-induced DRESS syndrome in a patient with asymptomatic gout.
    Ann Allergy Asthma Immunol
    2011
    107
    A26
    .
    CrossRef
  71. Kamatani
    N
    Fujimori
    S
    Hada
    T
    Hosoya
    T
    Kohri
    K
    Nakamura
    T
    et al
    Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
    J Clin Rheumatol
    2011
    17
    S50
    6
    PubMed
    CrossRef
    PubMed
  72. Yaylaci
    S
    Demir
    MV
    Temiz
    T
    Tamer
    A
    Uslan
    MI
    Allopurinol-induced DRESS syndrome.
    Indian J Pharmacol
    2012
    44
    412
    4
    PubMed
    CrossRef
    PubMed
  73. Schumacher
    HR
    Jr
    Becker
    MA
    Lloyd
    E
    MacDonald
    PA
    Lademacher
    C
    Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study.
    Rheumatology (Oxford)
    2009
    48
    188
    94
    PubMed
    CrossRef
    PubMed
  74. Lee
    MH
    Stocker
    SL
    Anderson
    J
    Phillips
    EJ
    Nolan
    D
    Williams
    KM
    et al
    Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?
    Intern Med J
    2012
    42
    411
    6
    PubMed
    CrossRef
    PubMed
  75. Hande
    KR
    Noone
    RM
    Stone
    WJ
    Severe allopurinol toxicity.
    Description and guidelines for prevention in patients with renal insufficiency. Am J Med
    1984
    76
    47
    56
    PubMed
  76. Chen
    IH
    Kuo
    MC
    Hwang
    SJ
    Chang
    JM
    Chen
    HC
    Allopurinol-induced severe hypersensitivity with acute renal failure.
    Kaohsiung J Med Sci
    2005
    21
    228
    32
    PubMed
    CrossRef
    PubMed
  77. Kumar
    A
    Edward
    N
    White
    MI
    Johnston
    PW
    Catto
    GR
    Allopurinol, erythema multiforme, and renal insufficiency.
    BMJ
    1996
    312
    173
    4
    PubMed
    CrossRef
    PubMed
  78. Lupton
    GP
    Odom
    RB
    The allopurinol hypersensitivity syndrome.
    J Am Acad Dermatol
    1979
    1
    365
    74
    PubMed
    CrossRef
    PubMed
  79. Chung
    WH
    Chang
    WC
    Stocker
    SL
    Juo
    CG
    Graham
    GG
    Lee
    MH
    et al
    Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin.
    Ann Rheum Dis
    2015
    74
    2157
    64
    PubMed
    CrossRef
    PubMed
  80. Singh
    JA
    Yang
    S
    Foster
    J
    Increased risk of skin reactions with gout medications: an analysis of VA databases.
    Arthritis Rheumatol
    2014
    66
    S71
    .
    CrossRef
  81. Ko
    TM
    Wu
    JY
    Chen
    YT
    Shen
    CY
    A prospective study of HLA*B-5801 genotyping in preventing allopurinol-induced severe cutaneous adverse reactions.
    Clin Transl Allergy
    2014
    4
    2
    .
    CrossRef
    PubMed
  82. Guy
    C
    Lebrun-Vignes
    B
    Jean-Pastor
    MJ
    Drug-induced toxic epidermal necrolysis and Stevens-Johnson syndrome: analysis of the French national pharmacovigilance database.
    Fundam Clin Pharmacol
    2014
    28
    65
    .
    CrossRef
    PubMed
  83. Bardin
    T
    Chales
    G
    Pascart
    T
    Flipo
    RM
    Roujeau
    JC
    Delayen
    A
    et al
    Is the rate of skin reactions to febuxostat increased in patients with a history of skin intolerance to allopurinol? A retrospective, hospital-based study involving 101 patients consecutively treated with allopurinol and febuxostat.
    Arthritis Rheumatol
    2014
    66
    S68
    .
    CrossRef
  84. Bardin
    T
    Chalès
    G
    Pascart
    T
    Flipo
    RM
    KorngEa
    H
    Roujeau
    JC
    et al
    Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
    Joint Bone Spine
    2016
    83
    314
    7
    PubMed
    CrossRef
    PubMed
  85. Becker
    MA
    Fitz-Patrick
    D
    Choi
    HK
    Dalbeth
    N
    Storgard
    C
    Cravets
    M
    et al
    An open-label, 6-month study of allopurinol safety in gout: the LASSO study.
    Semin Arthritis Rheum
    2015
    45
    174
    83
    PubMed
    CrossRef
    PubMed
  86. Cheng
    L
    Xiong
    Y
    Qin
    CZ
    Zhang
    W
    Chen
    XP
    Li
    J
    et al
    HLA-B*58:01 is strongly associated with allopurinol-induced severe cutaneous adverse reactions in Han Chinese patients: a multicentre retrospective case-control clinical study [Letter].
    Br J Dermatol
    2015
    173
    555
    8
    PubMed
    CrossRef
    PubMed
  87. Dennison
    EM
    Rubin
    KH
    Schwarz
    P
    Harvey
    NC
    Bone
    KW
    Cooper
    C
    et al
    Is allopurinol use associated with an excess risk of osteoporotic fracture?
    A National Prescription Registry study. Arch Osteoporos
    2015
    10
    36
    .
    PubMed
    CrossRef
  88. Ko
    TM
    Tsai
    CY
    Chen
    SY
    Chen
    KS
    Yu
    KH
    Chu
    CS
    et al
    Taiwan Allopurinol-SCAR Consortium
    Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study.
    BMJ
    2015
    351
    h4848
    .
    PubMed
    CrossRef
    PubMed
  89. Yang
    CY
    Chen
    CH
    Deng
    ST
    Huang
    CS
    Lin
    YJ
    Chen
    YJ
    et al
    Allopurinol use and risk of fatal hypersensitivity reactions: a nationwide population-based study in Taiwan.
    JAMA Intern Med
    2015
    175
    1550
    7
    PubMed
    CrossRef
    PubMed
  90. Schumacher
    HR
    Jr
    Becker
    MA
    Wortmann
    RL
    Macdonald
    PA
    Hunt
    B
    Streit
    J
    et al
    Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Arthritis Rheum
    2008
    59
    1540
    8
    PubMed
    CrossRef
    PubMed
  91. Becker
    MA
    Schumacher
    HR
    Jr
    Wortmann
    RL
    MacDonald
    PA
    Eustace
    D
    Palo
    WA
    et al
    Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
    N Engl J Med
    2005
    353
    2450
    61
    PubMed
    CrossRef
    PubMed
  92. Becker
    MA
    Schumacher
    HR
    Espinoza
    LR
    Wells
    AF
    MacDonald
    P
    Lloyd
    E
    et al
    The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial.
    Arthritis Res Ther
    2010
    12
    R63
    .
    PubMed
    CrossRef
    PubMed
  93. Becker
    MA
    Schumacher
    HR
    MacDonald
    PA
    Lloyd
    E
    Lademacher
    C
    Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    J Rheumatol
    2009
    36
    1273
    82
    PubMed
    CrossRef
    PubMed
  94. Taylor
    TH
    Mecchella
    JN
    Larson
    RJ
    Kerin
    KD
    Mackenzie
    TA
    Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial.
    Am J Med
    2012
    125
    1126
    1134
    PubMed
    CrossRef
    PubMed
  95. Becker
    MA
    Schumacher
    HR
    Jr
    Wortmann
    RL
    MacDonald
    PA
    Palo
    WA
    Eustace
    D
    et al
    Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
    Arthritis Rheum
    2005
    52
    916
    23
    PubMed
    CrossRef
    PubMed
  96. Rundles
    RW
    Metz
    EN
    Silberman
    HR
    Allopurinol in the treatment of gout.
    Ann Intern Med
    1966
    64
    229
    58
    CrossRef
    PubMed
  97. Paulus
    HE
    Schlosstein
    LH
    Godfrey
    RG
    Klinenberg
    JR
    Bluestone
    R
    Prophylactic colchicine therapy of intercritical gout.
    A placebo-controlled study of probenecid-treated patients. Arthritis Rheum
    1974
    17
    609
    14
    PubMed
  98. Hollingworth
    P
    Reardon
    JA
    Scott
    JT
    Acute gout during hypouricaemic therapy: prophylaxis with colchicine [Letter].
    Ann Rheum Dis
    1980
    39
    529
    .
    PubMed
    CrossRef
    PubMed
  99. Zhang
    W
    Doherty
    M
    Bardin
    T
    Pascual
    E
    Barskova
    V
    Conaghan
    P
    et al
    EULAR Standing Committee for International Clinical Studies Including Therapeutics
    EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).
    Ann Rheum Dis
    2006
    65
    1312
    24
    PubMed
    CrossRef
    PubMed
  100. Khanna
    D
    Fitzgerald
    JD
    Khanna
    PP
    Bae
    S
    Singh
    MK
    Neogi
    T
    et al
    American College of Rheumatology
    2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.
    Arthritis Care Res (Hoboken)
    2012
    64
    1431
    46
    PubMed
    CrossRef
    PubMed
  101. Firestein
    GS
    Kelley
    WN
    Budd
    RC
    Gabriel
    SE
    McInnes
    IB
    O'Dell
    JR
    Kelley's Textbook of Rheumatology, Volume 1.
    Philadelphia
    Elsevier Health Sciences
    2012
    1545
    .
  102. Becker
    MA
    MacDonald
    PA
    Hunt
    BJ
    Lademacher
    C
    Joseph-Ridge
    N
    Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy.
    Nucleosides Nucleotides Nucleic Acids
    2008
    27
    585
    91
    PubMed
    CrossRef
    PubMed
  103. Wu
    EQ
    Patel
    PA
    Mody
    RR
    Yu
    AP
    Cahill
    KE
    Tang
    J
    et al
    Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?
    J Rheumatol
    2009
    36
    1032
    40
    PubMed
    CrossRef
    PubMed
  104. Halpern
    R
    Fuldeore
    MJ
    Mody
    RR
    Patel
    PA
    Mikuls
    TR
    The effect of serum urate on gout flares and their associated costs: an administrative claims analysis.
    J Clin Rheumatol
    2009
    15
    3
    7
    PubMed
    CrossRef
    PubMed
  105. Sarawate
    CA
    Patel
    PA
    Schumacher
    HR
    Yang
    W
    Brewer
    KK
    Bakst
    AW
    Serum urate levels and gout flares: analysis from managed care data.
    J Clin Rheumatol
    2006
    12
    61
    5
    PubMed
    CrossRef
    PubMed
  106. Hamburger
    MI
    Tesser
    JRP
    Skosey
    JL
    Morton
    AH
    Kilgore
    KM
    Patterns of gout treatment and related outcomes in US community rheumatology practices: the relation between gout flares, time in treatment, serum uric acid level and urate lowering therapy [Abstract].
    Arthritis Rheum
    2012
    64 Suppl 10
    1904
    .
  107. Khanna
    PP
    Baumgartner
    S
    Khanna
    D
    Storgard
    C
    Morlock
    R
    Assessing SUA, flare rates, and tophi in patients with gout treated xanthine oxidase inhibitors in the United States.
    Ann Rheum Dis
    2013
    72
    A770
    .
  108. Terkeltaub
    R
    Perez-Ruiz
    F
    Storgard
    C
    Fung
    M
    Kopicko
    J
    Dalbeth
    N
    Relationship between sustained lowering of serum urate levels and improvements in gout flares and tophus area: pooled exploratory analysis of gout subjects receiving lesinurad and xanthine oxidase inhibitor combination therapy.
    Ann Rheum Dis
    2015
    74
    771
    2
    CrossRef
  109. Zleik
    N
    Michet
    CJ
    Khun
    H
    Crowson
    CS
    Matteson
    EL
    Bongartz
    T
    The risk of subsequent attacks in patients with incident gout: a population-based study.
    Arthritis Rheum
    2013
    65 Suppl 10
    S853
    .
  110. Krishnan
    E
    Akhras
    KS
    Sharma
    H
    Marynchenko
    M
    Wu
    E
    Tawk
    RH
    et al
    Serum urate and incidence of kidney disease among veterans with gout.
    J Rheumatol
    2013
    40
    1166
    72
    PubMed
    CrossRef
    PubMed
  111. Kim
    SC
    Schneeweiss
    S
    Choudhry
    N
    Liu
    J
    Glynn
    RJ
    Solomon
    DH
    Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
    Am J Med
    2015
    128
    653
    .
    PubMed
    CrossRef
    PubMed
  112. Jordan
    KM
    Cameron
    JS
    Snaith
    M
    Zhang
    W
    Doherty
    M
    Seckl
    J
    et al
    British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG)
    British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.
    Rheumatology (Oxford)
    2007
    46
    1372
    4
    PubMed
    CrossRef
    PubMed
  113. Loebl
    WY
    Scott
    JT
    Withdrawal of allopurinol in patients with gout.
    Ann Rheum Dis
    1974
    33
    304
    7
    PubMed
    CrossRef
    PubMed
  114. Perez-Ruiz
    F
    Herrero-Beites
    AM
    Carmona
    L
    A two-stage approach to the treatment of hyperuricemia in gout: the “dirty dish” hypothesis.
    Arthritis Rheum
    2011
    63
    4002
    6
    PubMed
    CrossRef
    PubMed
  115. Perez-Ruiz
    F
    Atxotegi
    J
    Hernando
    I
    Calabozo
    M
    Nolla
    JM
    Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study.
    Arthritis Rheum
    2006
    55
    786
    90
    PubMed
    CrossRef
    PubMed
  116. Janssens
    HJ
    Lucassen
    PL
    Van de Laar
    FA
    Janssen
    M
    Van de Lisdonk
    EH
    Systemic corticosteroids for acute gout.
    Cochrane Database Syst Rev.
    2008
    CD005521
    .
    PubMed
  117. van Echteld
    I
    Wechalekar
    MD
    Schlesinger
    N
    Buchbinder
    R
    Aletaha
    D
    Colchicine for acute gout.
    Cochrane Database Syst Rev.
    2014
    CD006190
    .
    PubMed
  118. van Durme
    CM
    Wechalekar
    MD
    Buchbinder
    R
    Schlesinger
    N
    van der Heijde
    D
    Landewé
    RB
    Non-steroidal anti-inflammatory drugs for acute gout.
    Cochrane Database Syst Rev.
    2014
    CD010120
    .
    PubMed
  119. Khanna
    PP
    Gladue
    HS
    Singh
    MK
    FitzGerald
    JD
    Bae
    S
    Prakash
    S
    et al
    Treatment of acute gout: a systematic review.
    Semin Arthritis Rheum
    2014
    44
    31
    8
    PubMed
    CrossRef
    PubMed
Figure.

Literature flow diagram.

* The number of included studies for this article differs from the number of included studies in the evidence report (3) because this review did not address all of the key questions addressed in the report.

† Results for this question are not included in this article. See the evidence report (3).

Image: M160461ff1_Figure_Literature_flow_diagram

Appendix Table 1. Detailed Search Methods

Image: M160461tt4_Appendix_Table_1_Detailed_Search_Methods
Appendix Table 1. Detailed Search Methods

Table 1. Key Trials of Treatments for Acute Gout

Image: M160461tt1_Table_1_Key_Trials_of_Treatments_for_Acute_Gout
Table 1. Key Trials of Treatments for Acute Gout

Appendix Table 2. Randomized, Controlled Trials of NSAID Versus NSAID for Treatment of Acute Gout

Image: M160461tt5_Appendix_Table_2_Randomized_Controlled_Trials_of_NSAID_Versus_NSAID_for_Treatment_of
Appendix Table 2. Randomized, Controlled Trials of NSAID Versus NSAID for Treatment of Acute Gout

Table 2. Key Trials of Urate-Lowering Therapy in Patients With Gout

Image: M160461tt2_Table_2_Key_Trials_of_Urate-Lowering_Therapy_in_Patients_With_Gout
Table 2. Key Trials of Urate-Lowering Therapy in Patients With Gout

Appendix Table 3. Adverse Events of Urate-Lowering Therapy From Selected Randomized, Controlled Trials*

Image: M160461tt6_Appendix_Table_3_Adverse_Events_of_Urate-Lowering_Therapy_From_Selected_Randomized_Co
Appendix Table 3. Adverse Events of Urate-Lowering Therapy From Selected Randomized, Controlled Trials*

Table 3. Summary of Prior Knowledge, Findings From the Systematic Review, and Strength of Evidence, by Key Question

Image: M160461tt3_Table_3_Summary_of_Prior_Knowledge_Findings_From_the_Systematic_Review_and_Strength_o
Table 3. Summary of Prior Knowledge, Findings From the Systematic Review, and Strength of Evidence, by Key Question

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

This feature is available only to Registered Users

Subscribe/Learn More
Submit a Comment

0 Comments

PDF
Not Available
Citations
Citation

Shekelle PG, Newberry SJ, FitzGerald JD, Motala A, O'Hanlon CE, Tariq A, et al. Management of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2017;166:37–51. doi: 10.7326/M16-0461

Download citation file:

  • RIS (Zotero)
  • EndNote
  • BibTex
  • Medlars
  • ProCite
  • RefWorks
  • Reference Manager

© 2018

×
Permissions

Published: Ann Intern Med. 2017;166(1):37-51.

DOI: 10.7326/M16-0461

Published at www.annals.org on 1 November 2016

©
2016 American College of Physicians
10 Citations

See Also

To Treat or Not to Treat (to Target) in Gout
The Long and Winding Road to Clinical Guidelines on the Diagnosis and Management of Gout
Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians
Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians
Diagnosis of Gout: A Systematic Review in Support of an American College of Physicians Clinical Practice Guideline
Management of Gout
Management of Gout
View MoreView Less

Related Articles

Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine; 166 (1): 58-68
Guideline: In acute gout, steroids, NSAIDs, or low-dose colchicine recommended; lifestyle changes not supported
Annals of Internal Medicine; 166 (4): JC14
Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians
Annals of Internal Medicine; 166 (1): 52-57
Annals for Educators - 3 January 2017
Annals of Internal Medicine; 166 (1): ED1
View MoreView Less

Journal Club

Guideline: In acute gout, steroids, NSAIDs, or low-dose colchicine recommended; lifestyle changes not supported
Annals of Internal Medicine; 166 (4): JC14
Allopurinol during acute gout attacks did not differ from delayed allopurinol for pain or recurrence
Annals of Internal Medicine; 158 (8): JC6
Prednisolone was equivalent to indomethacin for pain reduction in acute gout
Annals of Internal Medicine; 164 (10): JC51
Risk for septic arthritis was increased in adults with incident diagnosis of gout
Annals of Internal Medicine; 163 (12): JC12
View MoreView Less

Related Point of Care

Gout
Annals of Internal Medicine; 165 (1): ITC1-ITC16
Gout
Annals of Internal Medicine; 152 (3): ITC2-1
Osteoarthritis
Annals of Internal Medicine; 147 (3): ITC8-1
View MoreView Less

Related Topics

Gout
Rheumatology

Gout, Rheumatology.

PubMed Articles

Associations between Uric Acid Level and 3-Month Functional Outcome in Acute Ischemic Stroke Patients Treated with/without Edaravone.
Cerebrovasc Dis 2018;
Risk factors for type 2 diabetes mellitus: An exposure-wide umbrella review of meta-analyses.
PLoS One 2018;13(3):e0194127.
View More

Results provided by: PubMed

CME/MOC Activity Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
The Comments Feature Requires Users to be Registered and Logged In.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
link to top

Content

  • Home
  • Latest
  • Issues
  • Channels
  • CME/MOC
  • In the Clinic
  • Journal Club
  • Web Exclusives

Information For

  • Author Info
  • Reviewers
  • Press
  • Readers
  • Institutions / Libraries / Agencies
  • Advertisers

Services

  • Subscribe
  • Renew
  • Alerts
  • Current Issue RSS
  • Online First RSS
  • In the Clinic RSS
  • Reprints & Permissions
  • Contact Us
  • Help
  • About Annals
  • About Mobile
  • Patient Information
  • Teaching Tools
  • Annals in the News
  • Share Your Feedback

Awards

  • Personae Photography Prize
  • Junior Investigator Awards
  • Poetry Prize

Other Resources

  • ACP Online
  • Career Connection
  • ACP Advocate Blog
  • ACP Journal Wise

Follow Annals On

  • Twitter Link
  • Facebook Link
acp link acp
silverchair link silverchair

Copyright © 2018 American College of Physicians. All Rights Reserved.

Print ISSN: 0003-4819 | Online ISSN: 1539-3704

Privacy Policy

|

Conditions of Use

×

You need a subscription to this content to use this feature.

×
PDF Downloads Require Access to the Full Article.
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
INSTITUTIONAL SIGN IN
Open Athens|Shibboleth|Log In
Annals of Internal Medicine
PURCHASE OPTIONS
Buy This Article|Subscribe
You will be redirected to acponline.org to sign-in to Annals to complete your purchase.
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×
Access to this Free Content Requires Users to be Registered and Logged In. Please Choose One of the Following Options
Sign in below to access your subscription for full content
INDIVIDUAL SIGN IN
Sign In|Set Up Account
You will be directed to acponline.org to register and create your Annals account
Annals of Internal Medicine
CREATE YOUR FREE ACCOUNT
Create Your Free Account|Why?
To receive access to the full text of freely available articles, alerts, and more. You will be directed to acponline.org to complete your registration.
×